Yassine Amrani received his degrees (summa com laude) from the University Louis Pasteur in Strasbourg (France). He started his academic career at the University Of Pennsylvania School Of Medicine in Philadelphia (US), where he received his first appointment as an Assistant Professor of Medicine. In 2007, he moved to the University Of Leicester School Of Medicine in the UK as Associate Professor in Respiratory Immunology later as Principal Investigator at the NIHR BRC (respiratory). He is now working for AstraZeneca in Cambridge. His main research goal while in academia was to understand the basic mechanisms that contribute to the persistence, progression, and severity of lung diseases. His group focused on airway smooth muscle (ASM) for being the main culprit of driving acute asthma attacks. His group identified pathways in ASM that could drive many therapy-resistant features such as bronchial hyperresponsiveness (BHR), airway remodeling, and inflammation that include pro-asthmatic factors (TH1 and Th2 cytokines, growth factors), cell-cell interactions (involving mast cells) as well as associated pathways (RTK, JAK/STAT, phosphatase). Yassine Amrani received over $6 million worth of funding as PI and Co-I and has published >110 articles with an H-index of 52 (Google Scholar). He served as a reviewer and panel member for numerous funding bodies (France, US, UK, Ireland, Canada, etc..), and prestigious medical journals.
